Heather McSharry - Aug 5, 2022 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Role
Director
Signature
By: /s/Adam Guttmann, as attorney in fact For: Heather Ann McSharry
Stock symbol
JAZZ
Transactions as of
Aug 5, 2022
Transactions value $
-$587,618
Form type
4
Date filed
8/9/2022, 06:24 PM
Previous filing
Aug 10, 2021
Next filing
Aug 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAZZ Ordinary Shares Award $0 +2.56K +22.94% $0.00 13.7K Aug 5, 2022 Direct F1
transaction JAZZ Ordinary Shares Sale -$180K -1.18K -8.59% $152.32 12.5K Aug 8, 2022 Direct F2
transaction JAZZ Ordinary Shares Options Exercise $442K +8K +63.76% $55.28 20.5K Aug 8, 2022 Direct
transaction JAZZ Ordinary Shares Sale -$850K -5.5K -26.77% $154.59 15K Aug 8, 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JAZZ Non-Qualified Stock Option (right to buy) Options Exercise $0 -8K -100% $0.00* 0 Aug 8, 2022 Ordinary Shares 8K $55.28 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 28, 2023.
F2 Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.48 to $154.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 This option was granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Option Plan. Subject to the Reporting Person's continuous service and certain additional conditions, this option vested over three years from the Vesting Commencement Date, with 1/3 that vested on the first anniversary of the Vesting Commencement Date and the remainder vested in 24 equal monthly installments thereafter.